Retatrutide
An investigational GIP/GLP-1/glucagon triple receptor agonist.
Identity
- Class
- GIP/GLP-1/glucagon triple agonist (acylated peptide)
- Source
- Synthetic; engineered tri-agonist
- Receptor
- GIP + GLP-1 + glucagon receptors
Key properties
Approximate values for the native hormone. Engineered analogs are often deliberately larger and far longer-acting.
Mechanism
Retatrutide engages three receptors — GIP, GLP-1, and glucagon — from a single acylated peptide. Adding glucagon-receptor agonism recruits an energy-expenditure arm alongside the incretin effects. It is in clinical trials and not approved.
Reference notes
- A 'triple agonist' — incretin co-agonism extended to a third receptor.
- Glucagon-receptor agonism adds an energy-expenditure arm to the GLP-1/GIP effects.
- Investigational — under clinical study, not approved.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials · Metabolism open, 2024 · PMID 39318607
- 2.Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity · Diabetes care, 2024 · PMID 38843460